

Matthew J Price

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6172308/matthew-j-price-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

193
papers

12,588
citations

49
h-index

110
g-index

255
ext. papers

15,218
ext. citations

6.1
avg, IF

6.17
L-index

#	Paper	IF	Citations
193	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: A Patient-Level Analysis of the Disrupt CAD Studies 2022 , 1, 100011		1
192	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION.. <i>Circulation: Cardiovascular Interventions</i> , 2022 , CIRCINTERVENTIONS121011069	6	6
191	Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 741-750	5	0
190	Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAO Registry.. <i>Circulation: Cardiovascular Interventions</i> , 2022 ,	6	1
189	Letter by Price et al Regarding the Article, "Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial".. <i>Circulation</i> , 2022 , 145, e849	16.7	
188	Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials.. <i>JACC: Cardiovascular Interventions</i> , 2022 , 15, 950-961	5	0
187	Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 1785-1798	15.1	2
186	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX.. <i>Circulation: Cardiovascular Interventions</i> , 2021 , CIRCINTERVENTIONS120010390	6	0
185	Treatment and Outcomes of Device-Related Thrombus After Transcatheter Left Atrial Appendage Closure. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010889	6	
184	Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent. <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010144	6	15
183	Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions: Patient-Level Pooled Analysis of the Disrupt CAD Studies. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1337-1348	5	11
182	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 Update. <i>Circulation</i> , 2021 , 143, 583-596	16.7	31
181	Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention Insights from the CHAMPION program. <i>American Heart Journal Plus</i> , 2021 , 9, 100043		
180	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e008603	6	13
179	Diagnostic Accuracy of Nonhyperemic Pressure Ratios Using a Pressure Sensing Microcatheter: The ACIST-FFR Study. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1272-1275	5	
178	A Pilot Study of Monotherapy with a Non-Vitamin K-Antagonist Oral Anticoagulant following Watchman Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation. <i>Structural Heart</i> , 2020 , 4, 288-292	0.6	1
177	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 606-617	5	35

176	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020 , 382, 1208-1218	59.2	112
175	The NCDR Left Atrial Appendage Occlusion Registry. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1503-1518	15.1	92
174	Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE. <i>Interventional Cardiology Clinics</i> , 2020 , 9, 441-449	1.4	
173	Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2635-2646	15.1	70
172	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009565	6	17
171	Use of a Novel Septal Occluder Device for Left Atrial Appendage Closure in Patients With Postsurgical and Postlariat Leaks or Anatomies Unsuitable for Conventional Percutaneous Occlusion. <i>Circulation: Cardiovascular Interventions</i> , 2020 , 13, e009227	6	4
170	Risk of thromboembolic events after percutaneous left atrial appendage ligation in patients with atrial fibrillation: Long-term results of a multicenter study. <i>Heart Rhythm</i> , 2020 , 17, 175-181	6.7	15
169	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019 , 214, 134-141	4.9	24
168	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019 , 40, 2632-2653	9.5	169
167	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019 , 140, 240-261	16.7	183
166	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007445	6	
165	Newer-generation Metallic Stents: Design, Performance Characteristics, and Outcomes. <i>Interventional Cardiology Clinics</i> , 2019 , 8, 95-109	1.4	1
164	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019 , 12, e007342	6	5
163	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019 , 42, 797	3.3	2
162	Transcatheter Edge-to-Edge Repair for Primary (Degenerative) Mitral Regurgitation: Registries and Trials. <i>Interventional Cardiology Clinics</i> , 2019 , 8, 245-259	1.4	1
161	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019 , 12, 1521-1537	5	189
160	The functional assessment of patients with non-obstructive coronary artery disease: expert review from an international microcirculation working group. <i>EuroIntervention</i> , 2019 , 14, 1694-1702	3.1	17
159	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019 , 278, 217-222	3.2	3

158	Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage. <i>Journal of Cardiovascular Electrophysiology</i> , 2019 , 30, 511-516	2.7	13
157	Current State of Left Atrial Appendage Closure. <i>Current Cardiology Reports</i> , 2018 , 20, 42	4.2	7
156	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention: A Pooled, Patient-Level Analysis of the CHAMPION Trials (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation: Cardiovascular Interventions</i> , 2018 , 11, e005635	6	9
155	Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 564-574	15.1	21
154	Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2018 , 60, 542-549	8.5	5
153	The WATCHMAN Left Atrial Appendage Closure Device: Technical Considerations and Procedural Approach. <i>Interventional Cardiology Clinics</i> , 2018 , 7, 201-212	1.4	6
152	Left Atrial Appendage Occlusion: Data Update. <i>Interventional Cardiology Clinics</i> , 2018 , 7, 159-168	1.4	2
151	Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2018 , 19, 852-858	1.6	9
150	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 158-165	4.3	6
149	Cangrelor compared with clopidogrel in patients with prior myocardial infarction - Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 250, 49-55	3.2	4
148	Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, 253-259	2.7	19
147	Left Atrial Appendage Therapies 2018 , 473-487		
146	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update. <i>Circulation</i> , 2018 , 138, 527-536	16.7	164
145	New Volumetric Analysis Method for Stent Expansion and its Correlation With Final Fractional Flow Reserve and Clinical Outcome: An ILUMIEN I Substudy. <i>JACC: Cardiovascular Interventions</i> , 2018 , 11, 1467-1478 ²³	5.1	23
144	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018 , 205, 110-117	4.9	17
143	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018 , 270, 96-101	3.2	7
142	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. <i>EuroIntervention</i> , 2018 , 13, e1841-e1849	3.1	12
141	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018 , 39, 4112-4121	9.5	32

140	Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y Receptor Inhibiting Therapies". <i>Circulation</i> , 2018 , 137, 2310-2311	16.7	2
139	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017 , 89, 190-198	2.7	12
138	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017 , 69, 176-185	15.1	36
137	Synthesis and Characterization of 2-Phenylimidazo[1,2-a]pyridine: A Privileged Structure for Medicinal Chemistry. <i>Journal of Chemical Education</i> , 2017 , 94, 388-391	2.4	8
136	ANTARCTIC: platelet function testing to adjust therapy. <i>Lancet, The</i> , 2017 , 389, 1193	40	1
135	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors: An Exploratory Analysis From the CHAMPION Trials. <i>JAMA Cardiology</i> , 2017 , 2, 127-135	16.2	30
134	Cangrelor: Pharmacology, Clinical Data, and Role in Percutaneous Coronary Intervention. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 39-47	1.4	1
133	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. <i>American Heart Journal</i> , 2017 , 188, 147-155	4.9	2
132	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	6
131	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , 2017 , 136, 1955-1975	16.7	215
130	Imaging Assessment of the Interatrial Septum for Transcatheter Atrial Septal Defect and Patent Foramen Ovale Closure. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 505-524	1.4	5
129	Transcatheter Closure of Patent Foramen Ovale: Devices and Technique. <i>Interventional Cardiology Clinics</i> , 2017 , 6, 555-567	1.4	7
128	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX). <i>American Journal of Cardiology</i> , 2017 , 120, 1043-1048	3	9
127	First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 1381-1388	15.5	32
126	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention: Findings From CHAMPION PHOENIX. <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	6
125	5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 2964-2975	15.1	407
124	Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. <i>Heart Rhythm</i> , 2017 , 14, 19-24	6.7	69
123	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1093-1100	7	6

122	ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement). <i>Circulation: Cardiovascular Interventions</i> , 2017 , 10,	6	20
121	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1905-13	5	27
120	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	73
119	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016 , 9,	6	9
118	Clinical Implications of Leaks Following Left Atrial Appendage Ligation With the LARIAT Device. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1051-7	5	31
117	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial. <i>Circulation</i> , 2016 , 133, 248-55	16.7	23
116	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial. <i>Journal of the American College of Cardiology</i> , 2016 , 67, 596-8	15.1	20
115	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016 , 41, 374-83	5.1	22
114	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016 , 37, 1122-30	9.5	20
113	WATCHMAN: Trials and Registries Results. <i>Contemporary Cardiology</i> , 2016 , 169-180	0.1	
112	Catheter-Based Left Atrial Appendage Closure 2016 , 107-117		
111	Cardiovascular Interventions in the Modern Age: The Million Dollar Man. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1083-4	5	
110	"Off-Hours" Versus "On-Hours" Presentation in ST-Segment Elevation Myocardial Infarction: CHAMPION PHOENIX Findings. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 2385-2387	15.1	5
109	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition). <i>Circulation</i> , 2016 , 134, 723-33	16.7	23
108	Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. <i>European Heart Journal</i> , 2015 , 36, 3346-55	9.5	140
107	Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 2614-2623	15.1	328
106	An investigation of outcome expectancies as a predictor of treatment response for combat veterans with PTSD: comparison of clinician, self-report, and biological measures. <i>Depression and Anxiety</i> , 2015 , 32, 392-9	8.4	19
105	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015 , 36, 1762-71	9.5	218

104	Update on the guidelines for the management of ST-elevation myocardial infarction. <i>American Journal of Cardiology</i> , 2015 , 115, 3A-9A	3	10
103	A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 39, 8-14	5.1	13
102	Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]). <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 424-433	5	27
101	Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation. <i>Methodist DeBakey Cardiovascular Journal</i> , 2015 , 11, 94-9	2.1	1
100	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. <i>Cardiovascular Revascularization Medicine</i> , 2015 , 16, 450-4	1.6	11
99	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015 , 40, 317-22	5.1	23
98	A review of the LARIAT device: insights from the cumulative clinical experience. <i>SpringerPlus</i> , 2015 , 4, 522		16
97	Randomized Controlled Trial of Home-Based Telehealth Versus In-Person Prolonged Exposure for Combat-Related PTSD in Veterans: Preliminary Results. <i>Journal of Clinical Psychology</i> , 2015 , 71, 500-12	2.8	90
96	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, 1925-1932	5	61
95	Risk Assessment in Patient Selection for Transcatheter Aortic Valve Replacement. <i>Interventional Cardiology Clinics</i> , 2015 , 4, 1-12	1.4	3
94	Reply: Differences in experience with a new delivery device for LAA ligation among various U.S. centers. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 405-406	15.1	0
93	Impingement of left main ostium after device occlusion of paravalvular leak post-transcatheter aortic valve replacement. <i>JACC: Cardiovascular Interventions</i> , 2015 , 8, e1-2	5	
92	Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 565-72	15.1	161
91	Left atrial appendage closure to prevent stroke in patients with atrial fibrillation. <i>Circulation</i> , 2014 , 130, 202-12	16.7	27
90	Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 1-12	15.1	972
89	VerifyNow P2Y12 and Plateletworks Assays 2014 , 65-81		
88	Mechanical closure devices for atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2014 , 24, 225-31	6.9	2
87	Examination of prior experience with telehealth and comfort with telehealth technology as a moderator of treatment response for PTSD and depression in veterans. <i>International Journal of Psychiatry in Medicine</i> , 2014 , 48, 57-67	1	31

86	Cangrelor for treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 565-72	4	3
85	Conversations in cardiology: bridging antiplatelet therapy before surgery. <i>Catheterization and Cardiovascular Interventions</i> , 2014 , 83, 748-52	2.7	1
84	Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 560-3	15.4	2
83	Percutaneous management of late leak after lariat transcatheter ligation of the left atrial appendage in patients with atrial fibrillation at high risk for stroke. <i>Catheterization and Cardiovascular Interventions</i> , 2014 , 83, 664-9	2.7	29
82	mHealth: a mechanism to deliver more accessible, more effective mental health care. <i>Clinical Psychology and Psychotherapy</i> , 2014 , 21, 427-36	2.9	262
81	Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 112-120	15.1	73
80	Prevention and Management of Complications of Left Atrial Appendage Closure Devices. <i>Interventional Cardiology Clinics</i> , 2014 , 3, 301-311	1.4	8
79	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. <i>Journal of the American College of Cardiology</i> , 2013 , 62, 2261-73	15.1	693
78	Platelet reactivity after coronary stenting. <i>Lancet, The</i> , 2013 , 382, 583-4	40	1
77	Platelet function and genetic testing. <i>Journal of the American College of Cardiology</i> , 2013 , 62, S21-31	15.1	23
76	Pharmacogenomics in Interventional Pharmacology: Present Status and Future Directions. <i>Interventional Cardiology Clinics</i> , 2013 , 2, 615-625	1.4	2
75	Percutaneous closure of paravalvular leak after transcatheter aortic valve replacement. <i>JACC: Cardiovascular Interventions</i> , 2013 , 6, e6-8	5	15
74	Platelet function monitoring and clopidogrel. <i>Current Cardiology Reports</i> , 2013 , 15, 321	4.2	6
73	Effect of platelet inhibition with cangrelor during PCI on ischemic events. <i>New England Journal of Medicine</i> , 2013 , 368, 1303-13	59.2	560
72	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013 , 167, 2140-8	3.2	102
71	The role of clopidogrel in the management of ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2013 , 28, 381-8	2.1	
70	Predictors of completion of exposure therapy in OEF/OIF veterans with posttraumatic stress disorder. <i>Depression and Anxiety</i> , 2013 , 30, 1107-13	8.4	39
69	Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: the NINETY. <i>Catheterization and Cardiovascular Interventions</i> , 2013 , 82, 414-21	2.7	8

68	Evaluating the clinical usefulness of platelet function testing: considerations for the proper application and interpretation of performance measures. <i>Thrombosis and Haemostasis</i> , 2013 , 109, 808-167		32
67	Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery. <i>Heart Surgery Forum</i> , 2013 , 16, E60-9	0.7	4
66	Mindfulness Moderates the Relationship Between Disordered Eating Cognitions and Disordered Eating Behaviors in a Non-Clinical College Sample. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2012 , 34, 107-115	2	49
65	Outcome expectancy as a predictor of treatment response in cognitive behavioral therapy for public speaking fears within social anxiety disorder. <i>Psychotherapy</i> , 2012 , 49, 173-9	2.5	62
64	Prolonged exposure therapy for combat-related posttraumatic stress disorder: comparing outcomes for veterans of different wars. <i>Psychological Services</i> , 2012 , 9, 16-25	2.5	55
63	Genetic considerations. <i>Advances in Cardiology</i> , 2012 , 47, 100-13		3
62	Symptom overlap in posttraumatic stress disorder and major depression. <i>Psychiatry Research</i> , 2012 , 196, 267-70	9.9	115
61	The effect of exercise absence on affect and body dissatisfaction as moderated by obligatory exercise beliefs and eating disordered beliefs and behaviors. <i>Psychology of Sport and Exercise</i> , 2012 , 13, 500-508	4.2	16
60	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012 , 163, 768-776.e2	4.9	64
59	Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 1928-37	15.1	108
58	Left main percutaneous coronary intervention. <i>Journal of the American College of Cardiology</i> , 2012 , 60, 1605-13	15.1	23
57	Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 2338-43	15.1	91
56	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012 , 34, 44-55	5.1	113
55	Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 265-74	27.4	329
54	Response to Letters Regarding Article, Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial. <i>Circulation</i> , 2012 , 125	16.7	1
53	Behavioral activation and therapeutic exposure: an investigation of relative symptom changes in PTSD and depression during the course of integrated behavioral activation, situational exposure, and imaginal exposure techniques. <i>Behavior Modification</i> , 2012 , 36, 580-99	2.5	69
52	Left atrial appendage occlusion for the reduction of stroke and embolism in patients with atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012 , 13, 131-7	1.9	3
51	Platelet Inhibitor Agents 2012 , 97-112		2

50	Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. <i>Journal of the American College of Cardiology</i> , 2011 , 58, 1945-54	15.1	339
49	The impact of cognitive behavioral therapy on post event processing among those with social anxiety disorder. <i>Behaviour Research and Therapy</i> , 2011 , 49, 132-7	5.2	53
48	Psychological flexibility mediates the relations between self-concealment and negative psychological outcomes. <i>Personality and Individual Differences</i> , 2011 , 50, 243-247	3.3	37
47	Clinical outcomes following predilation with a novel 1.25-mm diameter angioplasty catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2011 , 77, 510-4	2.7	3
46	Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. <i>Circulation</i> , 2011 , 124, 1132-7	16.7	331
45	Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists. <i>Biomarkers in Medicine</i> , 2011 , 5, 43-51	2.3	10
44	Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1097-105	27.4	959
43	Platelet-mediated thrombosis and drug-eluting stents. <i>Circulation: Cardiovascular Interventions</i> , 2011 , 4, 629-37	6	4
42	The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors. <i>Reviews in Cardiovascular Medicine</i> , 2011 , 12, 1-12	3.9	13
41	The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010 , 3, 277-83; discussion 283	6	8
40	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. <i>Journal of the American College of Cardiology</i> , 2010 , 56, 919-33	15.1	913
39	IMPACT OF PLATELET REACTIVITY ON CLINICAL OUTCOMES: A PATIENT LEVEL META-ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2010 , 55, A179.E1673	15.1	2
38	Utility of on-line three-dimensional transesophageal echocardiography during percutaneous atrial septal defect closure. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 75, 570-7	2.7	11
37	Three-year outcome of drug-eluting stent implantation for coronary artery bifurcation lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 75, 309-14	2.7	17
36	A novel technique for ultra-low contrast administration during angiography or intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010 , 75, 1076-83	2.7	39
35	Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. <i>JACC: Cardiovascular Interventions</i> , 2010 , 3, 1001-7	5	33
34	Bedside evaluation of thienopyridine antiplatelet therapy. <i>Circulation</i> , 2009 , 119, 2625-32	16.7	111
33	Safety and performance of targeted renal therapy: the Be-RITe! Registry. <i>Journal of Endovascular Therapy</i> , 2009 , 16, 1-12	2.5	40

32	Monitoring platelet function to reduce the risk of ischemic and bleeding complications. <i>American Journal of Cardiology</i> , 2009 , 103, 35A-39A	3	24
31	Relation of periprocedural bleeding complications and long-term outcome in patients undergoing percutaneous coronary revascularization (from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] Trial). <i>American Journal of Cardiology</i> , 2009 , 103, 917-22	3	14
30	Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2009 , 103, 1339-43	3	126
29	Identifying the "optimal" duration of dual antiplatelet therapy after drug-eluting stent revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009 , 2, 1279-85	5	29
28	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009 , 157, 818-24, 824.e1	4.9	92
27	The Role of Psychological Flexibility in Mental Health Stigma and Psychological Distress for the Stigmatizer. <i>Journal of Social and Clinical Psychology</i> , 2009 , 28, 1244-1262	1.6	34
26	Dynamics of platelet functional recovery following a clopidogrel loading dose in healthy volunteers. <i>American Journal of Cardiology</i> , 2008 , 102, 790-5	3	26
25	Greater expectations: using hierarchical linear modeling to examine expectancy for treatment outcome as a predictor of treatment response. <i>Behavior Therapy</i> , 2008 , 39, 398-405	4.8	59
24	Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. <i>European Heart Journal</i> , 2008 , 29, 992-1000	9.5	536
23	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. <i>American Heart Journal</i> , 2008 , 155, 274-83	4.9	152
22	New antiplatelet therapies in development. <i>American Journal of Health-System Pharmacy</i> , 2008 , 65, S11-5; quiz S16-8	2.2	1
21	□ threshold of platelet reactivity for ischaemic events?□ and □ the optimal threshold of high post-treatment platelet reactivity could be defined by a point-of care VerifyNow P2Y12 assay□ reply. <i>European Heart Journal</i> , 2008 , 29, 2187-2187	9.5	
20	Change we can believe in: the hyper-evolution of percutaneous coronary intervention for unprotected left main disease with drug-eluting stents. <i>Circulation: Cardiovascular Interventions</i> , 2008 , 1, 164-6	6	2
19	Antiplatelet therapy in acute coronary syndromes. <i>Current Cardiology Reports</i> , 2008 , 10, 327-33	4.2	5
18	The off- versus on-label use of medical devices in interventional cardiovascular medicine: clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2008 , 72, 500-4	2.7	8
17	Clopidogrel desensitization after drug-eluting stent placement. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 2039-43	15.1	39
16	Intracoronary radiation therapy for multi-drug resistant in-stent restenosis: initial clinical experience. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 69, 132-4	2.7	8
15	Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial). <i>American Journal of Cardiology</i> , 2007 , 100, 1099-102	3	15

14	Utility of three-dimensional reconstruction of coronary angiography to guide percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2007 , 69, 479-82	2.7	55
13	Diesel Engine Turbocharger Rebuild and Experimental Testing 2007 , 485		
12	The effect of granulocyte colony stimulating factor on regional and global myocardial function in the porcine infarct model. <i>International Journal of Cardiology</i> , 2007 , 116, 225-30	3.2	9
11	Rescue percutaneous coronary intervention early after coronary artery bypass grafting in the drug-eluting stent era. <i>American Journal of Cardiology</i> , 2006 , 97, 789-91	3	6
10	Differential effects between intravenous and targeted renal delivery of fenoldopam on renal function and blood pressure in patients undergoing cardiac catheterization. <i>American Journal of Cardiology</i> , 2006 , 97, 1076-81	3	38
9	Onset and offset of platelet inhibition after high-dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. <i>American Journal of Cardiology</i> , 2006 , 98, 681-4	3	119
8	Early- and medium-term outcomes after paclitaxel-eluting stent implantation for sirolimus-eluting stent failure. <i>American Journal of Cardiology</i> , 2006 , 98, 1345-8	3	25
7	Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2006 , 68, 352-6	2.7	8
6	Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 871-7	15.1	169
5	Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. <i>International Journal of Cardiology</i> , 2006 , 111, 231-9	3.2	161
4	Unprotected Left Main Coronary Intervention with Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2006 , 19, S21-S26	1.8	4
3	A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting. <i>Journal of Invasive Cardiology</i> , 2006 , 18, 169-73	0.7	2
2	Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2005 , 65, 208-11	2.7	26
1	Stem cell repair of infarcted myocardium: an overview for clinicians. <i>Circulation</i> , 2003 , 108, 1139-45	16.7	127